Sunday, June 21, 2020 1:02:20 AM
CORONAVIRUS June 19, 2020
By Helena Oliviero, The Atlanta Journal-Constitution
Excerpt:
Reisman knew about a post-COVID trial for survivors of mild to moderate COVID-19 symptoms. Riley enrolled in the clinical trial for leronlimab, a drug that was originally developed to treat HIV, but is showing promise in the coronavirus fight.
He had four injections in his stomach over two weeks.Riley said he immediately felt better. He returned to a faster pace, his blood pressure returned to normal and the other symptoms – the anxiety, the insomnia — faded.It’s possible he was given a placebo or perhaps it was time that helped him heal, but Riley is confident that it was the leronlimab.
A lab technician works during research on coronavirus, COVID-19, at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. Janssen Pharmaceutical hopes to begin clinical trials on a potential vaccine for COVID-19 in the middle of the summer.
Doctor who was also COVID-19 patient Dr. Chris Recknor, a Gainesville internist who runs one of the six sites for the leronlimab clinical trial, is also a COVID-19 survivor.He first got sick in April, starting with an intense headache. Then, he started bumping into things and saw floaters in his eyes. Those aren’t the most common coronavirus symptoms, but he knew something wasn’t right and decided to get tested to, if nothing else, rule out the infectious virus. The test was positive.His conditioned worsened to the point where he thought he might have a heart attack.
He ended up in ER at Northeast Georgia Medical Center three times and was twice admitted for overnight stays.“I felt like my heart was pumping so hard, it felt like it was coming out of my ears,” he said.His physician at the hospital obtained “compassionate use” permission from the Food and Drug Administration to prescribe leronlimab.
https://www.ajc.com/lifestyles/health/for-some-with-covid-symptoms-can-linger-for-weeks-even-months/0rzLkWZWeXh0D2y3ezEqcN/
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 10:15:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM